title: New therapeutical approaches for non muscle invasive bladder cancer.
abstract: Non muscle invasive bladder cancer, given its high tendency to recur, coupled with an ever-present possibility to progress to potentially life-threatening muscle-invasive disease, remains a challenging clinical problem. Optimal management begins with early detection and accurate risk assessment through careful attention to clinical and histology features. Prevention of recurrence requires the sequential application of tools to completely remove all visible disease, avert reimplantation during surgical resection, ablate microscopic foci and prevent the emergence of new primary tumors amidst a field of carcinogen-exposed urothelium. Previously standard adjunctive intravesical chemo-immunotherapies are obtaining new vitality as optimization strategies, while new drugs and rational drug combinations provide the potential for improved efficacy with reduced toxicity. Novel therapeutic modalities under investigation include activation of the host immune system and enhancement of the cytotoxic effects of chemotherapeutic agents. New technological advances such as microwave chemothermotherapy offer further hope for better outcomes even for disease previously refractory to conservative measures. While much of this research is in the preclinical phase, the encouraging results of many of the studies discussed here suggest that testing in human trials should follow in the coming years. Yet despite these advances, aggressive surgical management involving bladder removal continues to be an indispensable life-saving maneuver that must be considered in all high-risk cases that fail to promptly respond to other measures. Although great strides continue to be made each year in the diagnosis and management of bladder cancer considerably more work needs to be done in order to improve the lives of our patients with this disease.
authors.affiliation: Department of Urology, Catholic University School of Medicine, Rome. dr.avolpe@gmail.com
authors.forename: Andrea
authors.initials: A
authors.lastname: Volpe
authors.forename: Marco
authors.initials: M
authors.lastname: Racioppi
authors.forename: Emilio
authors.initials: E
authors.lastname: Sacco
authors.forename: Luca
authors.initials: L
authors.lastname: Bongiovanni
authors.forename: Daniele
authors.initials: D
authors.lastname: D'Agostino
authors.forename: Emanuele
authors.initials: E
authors.lastname: Cappa
authors.forename: Francesco
authors.initials: F
authors.lastname: Pinto
authors.forename: Mario
authors.initials: M
authors.lastname: Gardi
authors.forename: Angelo
authors.initials: A
authors.lastname: Totaro
authors.forename: PierFrancesco
authors.initials: P
authors.lastname: Bassi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D007167:Immunotherapy; D008942:Mitoxantrone / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D006820:Hyaluronic Acid; D008942:Mitoxantrone; D017239:Paclitaxel